Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31178152

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2019 Jun 29
First author
Earl HM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2019 Jun 29;393(10191):2565-2567. doi: 10.1016/S0140-6736(19)30946-8.
    note
    Source null
    related pmid
    31178153
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2019 Nov;16(11):663-664. doi: 10.1038/s41571-019-0256-7.
    note
    Source null
    related pmid
    31341271
    relationship
    Comment in
  3. citation
    Lancet. 2020 Feb 15;395(10223):491-492. doi: 10.1016/S0140-6736(19)32549-8.
    note
    Source null
    related pmid
    32061289
    relationship
    Comment in

Authors and identifiers

  1. name
    Earl HM
    type
    Author
  2. name
    Hiller L
    type
    Author
  3. name
    Vallier AL
    type
    Author
  4. name
    Loi S
    type
    Author
  5. name
    McAdam K
    type
    Author
  6. name
    Hughes-Davies L
    type
    Author
  7. name
    Harnett AN
    type
    Author
  8. name
    Ah-See ML
    type
    Author
  9. name
    Simcock R
    type
    Author
  10. name
    Rea D
    type
    Author
  11. name
    Raj S
    type
    Author
  12. name
    Woodings P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Earl HM
    type
    Author
  2. name
    Hiller L
    type
    Author
  3. name
    Vallier AL
    type
    Author
  4. name
    Loi S
    type
    Author
  5. name
    McAdam K
    type
    Author
  6. name
    Hughes-Davies L
    type
    Author
  7. name
    Harnett AN
    type
    Author
  8. name
    Ah-See ML
    type
    Author
  9. name
    Simcock R
    type
    Author
  10. name
    Rea D
    type
    Author
  11. name
    Raj S
    type
    Author
  12. name
    Woodings P
    type
    Author
bibliography ids
  1. nci-bib-67b0ae83b974ef976e19c1df
book metadata
content sha256
28fb870295395ba4bc30f6864446adb00a4ce564cc30e6a5b320aa8289585ef0
document type
citation
dois
  1. 10.1016/S0140-6736(19)30650-6
electronic publication date
display
2019 Jun 6
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31178152
immutable id
pubmed:31178152@28fb870295395ba4bc30f6864446adb00a4ce564cc30e6a5b320aa8289585ef0
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10191
name
Lancet (London, England)
nlm unique id
2985213R
pages
2599-2612
volume
393
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2019 Jun 29;393(10191):2565-2567. doi: 10.1016/S0140-6736(19)30946-8.
    note
    Source null
    related pmid
    31178153
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2019 Nov;16(11):663-664. doi: 10.1038/s41571-019-0256-7.
    note
    Source null
    related pmid
    31341271
    relationship
    Comment in
  3. citation
    Lancet. 2020 Feb 15;395(10223):491-492. doi: 10.1016/S0140-6736(19)32549-8.
    note
    Source null
    related pmid
    32061289
    relationship
    Comment in
outcomes validated
false
pmid
31178152
provenance
batch id
23ffe1e2a9e160b6dca0
provider
NCBI PubMed ESummary
record sha256
08ea1e9a47de637a33327b1e0a4a68f16804422891854e7d8f80f4f340489d24
response sha256
d5cbfde8f87ba85b214c53aaf0e8fa33d70fec48dd4fde7745538180cd7e1841
retrieved at
2026-09-09T23:47:44.690737+00:00
publication date
display
2019 Jun 29
precision
day
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Equivalence Trial
  4. Journal Article
  5. Multicenter Study
  6. Randomized Controlled Trial
  7. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31178152/
title
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Preserved source evidence · Not medical advice